Company: ATHE
Filing Date: 2025-08-29
Form Type: 20-F
Source: 0001213900-25-082027
Chunk: 153

Company: ALTERITY THERAPEUTICS LTD
Filing Date: 2025-08-29
Form: 20-F
Item: Item 18
Chunk 153
---
ase/(increase) in other current assets (excepting term deposit)              1,081,363                      252,986                     (968,207   )
(Decrease)/increase in trade and other payables                                  (2,044,457   )                1,102,239                   (1,560,873   )
(Decrease) in other current liabilities                                             (99,861   )                  (11,935   )                        -    
Increase/(decrease) in provision for employee entitlements                          345,209                     (218,006   )                   78,685    
Net cash flows used in operating activities                                     (11,451,248   )              (12,605,824   )              (20,035,837   )
(b) Reconciliation of Cash and Cash Equivalents                                                                                                          
Cash and cash equivalents balance comprises:                                                                                                             
- cash and cash equivalents on hand                                              33,158,642                   12,638,885                   15,773,783    
Closing cash and cash equivalents balance                                        33,158,642                   12,638,885                   15,773,783    
   (c) Non-Cash Financing and Investing Activities
   There were no non-cash financing and investing activities during the years ended June 30, 2025, 2024 and 2023.

F-31

ALTERITY THERAPEUTICS LIMITED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – in Australian dollars (unless otherwise noted)

15. EXPENDITURE COMMITMENTS
   As of June 30, 2025 and 2024, the Group no longer has short term leases contracted for but not capitalized in the financial statements.   The majority of our contracts for research and development programs have a termination notice period of 30 days. As of June 30, 2025, we had research and development termination commitments approximating A$1.7 million. No liability has been recognised within our financial statements for this period. In addition, we have the ability to scale down our operations and prioritise our research and development programs to reduce expenditures.   
Details in relation to commitments under employee service agreements with Directors and Key Management Personnel are outlined in Note 21.

16. SHARE BASED PAYMENTS
   At the Annual General Meeting held on November 17, 2004, the shareholders approved the establishment of employee and consultant plans designed to reward directors, employees and consultants for their contributions to the Group.